On November 10, 2016 Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"), reported its financial results for the quarter ended September 30, 2016 (Press release, Provectus Pharmaceuticals, NOV 10, 2016, https://www.pvct.com/pressrelease.html?article=20161110.1 [SID1234516712]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Third Quarter Results and Balance Sheet Highlights
Our cash and cash equivalents were $5,178,076 at September 30, 2016, compared with $4,891,313 at June 30, 2016. As of December 31, 2015, cash and equivalents were $14,178,902.
Shareholders’ equity at September 30, 2016 was $5,309,712. This compares to shareholders’ equity of $9,140,166 at June 30, 2016, and $16,316,941 as of December 31, 2015.
For additional information regarding Provectus’ results of operations and financial condition for the third quarter ended September 30, 2016, please see Provectus’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2016.
Management will host its 2016 third quarter business update conference call on Monday, November 14, 2016 at 4 pm Eastern Standard Time. Management will provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.
Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately fifteen minutes before the call. A webcast will also be available at www.provectusbio.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until March 4, 2017 and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, and using the Conference ID # 13648197.